Sign in to view content

Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients With nAMD Following a Modified Manufacturing Process

Raj K. Maturi, MD

Video
Published 2019

Raj K. Maturi, MD

Late Breakers Symposium

Related

Brolucizumab: Will it Make a Differance
Andrew P. Schachat, MD
Updates from the Field
2018
FIDO Study: 10-Year Outcomes of Eyes Receiving Continuous, Fixed-Interval Dosing of Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Ivan J. Suner, MD, MBA
Annual Meeting Talks
2019
Brolucizumab for Neovascular AMD: The 2 Year HAWK and HARRIER Results
Pravin U. Dugel, MD
Updates from the Field
2018

Category: AMD-Neovascular

Neovascualar AMD Clinical Trials

See more